Melanoma — Trials, FDA Actions & Pivotal Research
34 updates aggregated from openFDA and ClinicalTrials.gov, covering trial milestones, FDA actions, and pivotal publications about Melanoma.
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
Drugs with Melanoma trials
Recruiting trials by city
Cities where Melanoma trials in our archive had recruiting sites. Each link lists every currently recruiting paid clinical trial at that location.
Updates
2026
- Results postedPembrolizumab Plus Radiotherapy Melanoma Trial Posts Mixed Survival Data· Apr 23, 2026· drug: Pembrolizumab
- Results postedPembrolizumab with L-NMMA Phase 1b Trial Identifies 20 mg/kg MTD· Apr 9, 2026· drug: Pembrolizumab
- Results postedNivolumab: Melanoma Patients Prefer Subcutaneous Administration in Phase 2 Trial· Apr 9, 2026· drug: Nivolumab
- Results postedKeytruda SC Formulation Preferred by Cancer Patients in Preference Study· Apr 8, 2026· drug: Pembrolizumab
- Results postedMelanoma Study Identifies 52 Genes Predictive of Immunotherapy Response· Apr 6, 2026
- Results postedMelanoma Prevention Program Posts Sun Protection Index Scores· Apr 3, 2026
- Results postedPembrolizumab Combination Trial for Solid Tumors Reports DLTs at High Dose· Mar 27, 2026· drug: Pembrolizumab
- Results postedPembrolizumab + Imiquimod Shows 8.1-Month Mean Response Duration in Melanoma· Mar 19, 2026· drug: Pembrolizumab
- Results postedMelanoma: AI Tool Shows High Accuracy for Early Detection· Mar 16, 2026
- Primary completionFianlimab Combination Melanoma Trial Reaches Primary Completion· Mar 12, 2026· drug: Fianlimab
- Results postedPembrolizumab + SRS for Brain Metastases Shows No Dose-Limiting Toxicities· Mar 9, 2026· drug: Pembrolizumab
- Results postedNivolumab-based Immunotherapy Shows Improved 2-Year OS in BRAFV600 Melanoma· Feb 18, 2026· drug: Nivolumab
- Results postedPembrolizumab Combination Shows Responses in Refractory Advanced Cancers· Jan 29, 2026· drug: Pembrolizumab
- Primary completionNivolumab Biosimilar Study in Melanoma Reaches Primary Completion· Jan 23, 2026· drug: Nivolumab
- Primary completionPembrolizumab Trial for Advanced Melanoma Reaches Primary Completion· Jan 12, 2026· drug: Pembrolizumab
- Results postedKeytruda + Ipilimumab Combo Shows Clinical Benefit in Brain Metastatic Melanoma· Jan 9, 2026· drug: Pembrolizumab
- Results postedNivolumab Plus Relatlimab Melanoma Trial Terminated· Jan 8, 2026· drug: Nivolumab
- Results postedMelanoma: UVR Protection Decision-Making Study Posts Results· Jan 7, 2026
2025
- Results postedLifileucel in Metastatic Melanoma Shows Objective Responses and Disease Control· Dec 9, 2025· drug: Lifileucel
- Results postedPembrolizumab/EDP1503 in Advanced Melanoma: Phase 2 Trial Terminated, No…· Dec 8, 2025· drug: Pembrolizumab
- Results postedPembrolizumab Plus BO-112 Shows 25% ORR in Unresectable Melanoma· Nov 26, 2025· drug: Pembrolizumab
- Results postedPembrolizumab + APX005M Combo Achieves Up to 66.7% ORR in Melanoma· Nov 21, 2025· drug: Pembrolizumab
- Results postedPembrolizumab Combination Trial Reports Low ORR in Melanoma, CRC, HCC· Oct 24, 2025· drug: Pembrolizumab
- Results postedAtezolizumab Trial for High-Risk Skin Cancers Terminated· Oct 22, 2025· drug: Atezolizumab
- Results postedNivolumab Monotherapy Outperforms Combination in Advanced Melanoma Trial· Sep 5, 2025· drug: Nivolumab
- Results postedPembrolizumab Safety Profile Evaluated in Indian Melanoma, NSCLC Patients· Aug 29, 2025· drug: Pembrolizumab
- Results postedPembrolizumab/Enoblituzumab Combination Reports Low DLTs in Refractory Cancers· Aug 11, 2025· drug: Pembrolizumab
- Primary completionNivolumab + Relatlimab SC Bioequivalence Trial in Melanoma Completes Primary…· Aug 4, 2025· drug: Nivolumab
- Results postedPembrolizumab Metastatic Melanoma Trial Terminated· Jul 25, 2025· drug: Pembrolizumab
- Results postedNivolumab Monotherapy Shows 23% Objective Response in Bladder Cancer· Jul 22, 2025· drug: Nivolumab
- Results postedAtezolizumab + Tiragolumab Combo Shows Lower Pathologic Response in Melanoma· Jul 18, 2025· drug: Atezolizumab
- Results postedSymptom Management for Young Adult Cancer Survivors Trial Results Posted· Jun 29, 2025
- Results postedNivolumab Combination Therapy Trial for Advanced Cancers Posts Safety Data· Jun 19, 2025· drug: Nivolumab
- Primary completionPembrolizumab Trial for Advanced Melanoma Reaches Primary Completion· May 30, 2025· drug: Pembrolizumab